Enhanced Telemedicine versus In-Person Evaluation for the Diagnosis of Skin Cancer, The SpotCheck Trial

PRIMARY OBJECTIVE:

I. To assess the concordance in biopsy recommendations between the in-person dermatologist evaluation and the enhanced telemedicine evaluation of participant-identified skin lesions concerning for skin cancer in a walk-in clinic setting.

SECONDARY OBJECTIVES:

I. To compare the diagnostic accuracy of the enhanced telemedicine method, and its separate individual components (Nevisense, teledermoscopy), to the in-person dermatologist with respect to the diagnosis of skin cancer (confirmed histopathologically).

II. To assess patient satisfaction and preferences (patient-centered outcomes) regarding the teledermatologist evaluation for skin lesions suspicious for skin cancer.

III. To determine the proportion of participant-selected skin lesions for which the Nevisense measurement would be considered appropriate by the in-person and teledermatologists.

IV. To create a database of dermoscopic images and Nevisense scores of the benign and malignant skin lesions encountered in the walk-in clinic setting.

OUTLINE:

Patients undergo photo imaging of skin lesions and measurements using Nevisense device for telemedicine evaluation followed by in-person skin lesion evaluation by dermatologist over 30-90 minutes. Patients may undergo biopsy if recommended by dermatologist or teledermatologist.